Coating Place, Inc. is a privately owned contract manufacturing organization specializing in pharmaceutical grade Wurster fluid bed coating services for encapsulation/microencapsulation of solid particulate materials such as powders, granules, crystals, and capsules. Services offered include pharmaceutical GMP contract manufacturing, process validation, technology transfer, scale-up, formulation development, feasibility studies, and GMP analytical laboratory support.Applications include controlled oral delivery such as enteric, delayed, or sustained release, taste, odor masking, and moisture or oxygen barrier application for Rx prescription, OTC, and controlled substance markets. Facilities are permitted for solvent applications; thus, allowing solvent, aqueous, and hot melt Wurster processing.

SIGA Technologies was founded in 1995 and is headquartered in New York, New York. SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of anti-infectives and antibiotics for the prevention and treatment of serious infectious diseases. SIGA company focus on products for use in defense against biological warfare agents, such as smallpox, arenaviruses (hemorrhagic fevers), and other category A viral agents. Its lead product, ST-246, is an orally administered anti-viral drug that targets orthopox viruses. SIGA's product candidates also include ST-294 and ST-193, which demonstrates antiviral activity in cell culture assays against arenavirus pathogens; and ST-669, a broad spectrum antiviral candidate, for various viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. In addition, it also has four drug series in the pre-clinical development stage, including ST-610 and ST-148 for dengue virus of the genus Flavivirus. SIGA company has license agreements, collaborative research arrangements, and contracts with National Institutes of Health and the United States Air Force.

Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products. The Company’s activity includes improving off-patent drug products for life cycle management and developing generic versions of controlled-release drug products. Its technology is applicable to develop delayed, sustained or targeted-release pellets, capsules, tablets, granules and powders. As of March 31, 2009, the Company had two products, Lodrane 24 and Lodrane 24D, being sold commercially, and a pipeline of five additional drug candidates under active development in the therapeutic areas that include pain management, allergy and infection. Of the products under development, ELI-216, a once-a-day, abuse-deterrent oxycodone product, and ELI-154, a once-a-day oxycodone product, are in clinical trials, and Elite has completed pilot studies on two of its other generic product candidates.

Skystar Bio-pharmaceutical Company ("Skystar") is one of China's leading manufacturers and distributors of vaccines and medicines for poultry, livestock and domestic pets. Skystar has over 173 products in its current product line and has over 50 more products in development. Skystar employs over 200 people in Production Facilities located in Hu Xian, Xi'an City, Shaanxi, Province, PRC.Skystar has recently opened (July of 2006) its new GMP Certified Facility that will increase production capabilities by 200%. The demand for veterinary medicines and vaccines in China far exceeds the supply and Skystar's plan is to capitalize on its new GMP Certified Facility to increase margins while increasing production to help meet the growing and overwhelming demand for its products.

SCOLR Pharma, Inc. is a specialty pharmaceutical company, which through its Controlled Delivery Technology (CDT) platforms, develops prescription, over-the-counter (OTC) and nutritional products. The Company has developed multiple private-label controlled release nutritional products incorporating its CDT platforms that are sold by national retailers. The Company’s lead product candidate is a CDT-based controlled release formulation of ibuprofen, an analgesic used for the treatment of pain, fever and inflammation. It completed the pivotal phase III trial to evaluate the safety and efficacy of its 12 hour CDT 600 milligram controlled release ibuprofen for the OTC market. In addition, the Company submitted its first abbreviated new drug application (ANDA) for its 12-hour pseudoephedrine product on August 5, 2008.

Protein Polymer Technologies, Inc. company was founded in 1988 and is based in San Diego, California. Protein Polymer Technologies, Inc., a biotechnology company, engages in the research, development, and production of bio-active devices to improve medical and surgical outcomes. The company, through its proprietary technology, produces molecular weight polymers that can be processed into a range of material forms, such as gels, sponges, films, and fibers. It also focuses on developing protein polymers that are used in products for tissue augmentation, tissue adhesives and sealants, and drug delivery devices. The company also develops and offers surgical tissue sealants that include tissue adhesives and sealants; wound healing and tissue regeneration products, including fabric dressings, synthetic materials, and biological materials; and urethral bulking agent that relieves female stress incontinence. In addition, it develops coating technology that modifies and improves surface properties of traditional biomedical devices.

ImClone Systems has one drug and it is making the most of it. The drug development company's only product on the market, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb in North America and with Merck KGaA elsewhere. ImClone is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. The company is also working on additional oncology-related antibody therapies. In 2008 ImClone was acquired by Eli Lilly for $6.5 billion, after rejecting bids from Bristol-Myers Squibb.

Solgar has been innovating and producing fine quality nutritional supplements since 1947. Our ongoing mission is to provide consumers with top-quality, innovative, science-based nutritional supplements to enhance their total health and well-being. We are committed to exclusively distributing our products in the natural products industry where knowledgeable retailers worldwide can guide consumers through the vast array of choices.

Peptimmune is pepped up about stopping the immune system when it malfunctions. The research-stage biotechnology company is focused on developing pharmaceuticals that treat medical conditions in which the body essentially attacks itself. Peptimmune conducts research and development programs on potential drug candidates targeting autoimmune and inflammatory ailments such as Crohn's disease, multiple sclerosis, and rheumatoid arthritis. The company partners with other pharmaceutical firms in some of its drug development efforts; it also relies on venture capital investors to help fund its research.

DOV Pharmaceutical, Inc. is a biopharmaceutical company focused on the development of product candidates for disorders of the central nervous system (CNS). The Company has drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The Company also has a drug development program subject to regulatory review, Indiplon, which is being developed as a treatment for insomnia. The Company has sublicensing agreements for the development and commercialization of certain product candidates with XTL Biopharmaceuticals, Inc. (XTL) for bicifadine, with Blue Note Pharmaceuticals, Inc. (Blue Note) for DOV diltiazem, and with Neurocrine Biosciences, Inc. (Neurocrine) for indiplon.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.